Dr. Schiff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Spruce St
Ste 100
Denver, CO 80230Phone+1 303-394-2828Fax+1 303-320-0242
Education & Training
SUNY Downstate Health Sciences UniversityFellowship, Rheumatology, 1974 - 1976
Albany Medical CenterResidency, Internal Medicine, 1972 - 1974- Albany Medical CenterInternship, Transitional Year, 1971 - 1972
State University of New York Downstate Medical Center College of MedicineClass of 1971
Certifications & Licensure
CO State Medical License 1976 - 2021
Clinical Trials
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis Start of enrollment: 2005 Dec 01
- Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia Start of enrollment: 2010 Jul 01
Publications & Presentations
PubMed
- 5 citationsDifferential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.Omar Jabado, Michael A Maldonado, Michael Schiff, Michael E Weinblatt, Roy Fleischmann
Rheumatology and Therapy. 2022-04-01 - 1 citationsCorrection to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifyin...Vibeke Strand, Janet Pope, Namita Tundia, Alan Friedman, Heidi S Camp
Arthritis Research & Therapy. 2020-06-09 - 16 citationsUpadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic...Vibeke Strand, Janet Pope, Namita Tundia, Alan Friedman, Heidi S Camp
Arthritis Research & Therapy. 2019-12-09
Press Mentions
Correction to: Upadacitinib Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Results from SELECT-NEXTJune 9th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
